Comparative analysis of the consumption of antidepressants in Ukraine, Estonia and Norway

Authors

DOI:

https://doi.org/10.15587/2519-4852.2023.281833

Keywords:

depression, antidepressants, pharmaceutical market, ATC/DDD methodology, consumption volumes, escitalopram, comparison of consumption volumes, Ukraine, Norway, Estonia

Abstract

Due to modern living conditions, the number of patients suffering from chronic depression is increasing every year. Antidepressants (AD) are one of the most popular drugs. In recent years, the demand for AD has increased in many countries of the world. The analysis of trends in the level and structure of AD consumption in Ukraine compared to other countries is relevant.

The aim. The purpose of the study was to study the assortment of AD in Ukraine for 2020-2021, as well as to analyze the volume and structure of AD consumption compared to similar data for Estonia and Norway.

Materials and methods. Marketing analysis of the range of drugs on the market and ATC/DDD-methodology were used to study the volume of drug consumption. The analysis of the assortment and consumption volumes of AD was carried out according to the data of the State Register of Medicinal Products of Ukraine and the analytical company "Proxima Research"/"Morion". Calculations of consumption volumes were made according to the ATC/DDD methodology in terms of DDDs per 1000 inhabitants per day (DID). The obtained results of the level and structure of AD consumption were compared with similar data on the official resources of the State representatives of medicinal products of Estonia and Norway.

Results. The obtained results showed that ADs in Ukraine during 2020-2021 were represented by 19 INNs, mostly drugs of foreign manufacturers. The pharmaceutical market was dominated by selective serotonin reuptake inhibitors (SSRIs). It was established that the consumption of AD among the population of Estonia exceeded the indicators in Ukraine by 12.2-13.6 times, and in Norway by 18.2-21.6 times. The leader in terms of consumption in the three studied countries was a representative of the SSRI group escitalopram, but its consumption in Estonia and Norway was higher than in Ukraine, respectively, by 7.7-9.4 times and by 16.8-21.3 times.

Conclusions. A significant difference in AD consumption may indicate that in Estonia and Norway, a greater number of patients with chronic depression seek medical help and receive pharmacotherapy than in Ukraine

Author Biographies

Oksana Tkachova, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Professor

Department of Pharmaceutical Management and Marketing

Larysa Iakovlieva, National Polytechnic University “Kharkiv Polytechnic Institute”

Doctor of Pharmaceutical Sciences, Professor

Department of General Pharmacy

Olga Gerasymova, National University of Pharmacy

PhD, Deputy Director

Educational and Scientific Institute of Applied Pharmacy

Yaroslava Butko, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Professor

Department of Pharmacology and Pharmacotherapy

Liliia Kovalenko, National University of Pharmacy

Department of Pharmaceutical Management

References

  1. Global Health Data Exchange (2021). Institute of Health Metrics and Evaluation.
  2. Maruta, N. O. (2021). Pryntsypy likuvannia depresii ta novitni mozhlyvosti suchasnykh antydepresantiv. Zdorovia Ukrainy, 2.
  3. Voloshyn, P. V., Maruta, N. O. (2015) Stratehiia okhorony psykhichnoho zdorovia naselennia Ukrainy: suchasni mozhlyvosti ta pereshkody. Ukrainskyi visnyk psykhonevrolohii, 23 (1 (82)), 5–11.
  4. Thapar, A., Eyre, O., Patel, V., Brent, D. (2022). Depression in young people. The Lancet, 400 (10352), 617–631. doi: https://doi.org/10.1016/s0140-6736(22)01012-1
  5. Monroe, S. M., Harkness, K. L. (2022). Major Depression and Its Recurrences: Life Course Matters. Annual Review of Clinical Psychology, 18 (1), 329–357. doi: https://doi.org/10.1146/annurev-clinpsy-072220-021440
  6. Chaban, O. S., Khaustova, O. O. (2022). Medical and psychological consequences of war distress in Ukraine: what do we expect and what should be taken into account when providing medical aid? Ukrainian Medical Journal, 4 (150). doi: https://doi.org/10.32471/umj.1680-3051.150.232297
  7. Sokolovskyi, D. (2022). Problemy psykhichnoho zdorovia naselennia u voiennyi chas ta shliakhy yikh rozviazannia. Zdorov´ya Ukrainy, 4, 8–10.
  8. National Health and Nutrition Examination Survey: 1988–2018 data documentation, codebook, and frequencies (2021). National Center for Health Statistics.
  9. Debra, J. (2020). Brody and Qiuping Gu. (2020) Antidepressant Use Among Adults: United States, 2015-2018. NCHS Data Brief No. 377. NCHS reports.
  10. Diaz-Camal, N., Cardoso-Vera, J. D., Islas-Flores, H., Gómez-Oliván, L. M., Mejía-García, A. (2022). Consumption and ocurrence of antidepressants (SSRIs) in pre- and post-COVID-19 pandemic, their environmental impact and innovative removal methods: A review. Science of The Total Environment, 829, 154656. doi: https://doi.org/10.1016/j.scitotenv.2022.154656
  11. Transforming the understanding and treatment of mental illnesses. Depression. (2017) National Institute of Mental Health.
  12. Yakovlieva, L. V., Bahlai, T. O., Tkachova, O. V., Pavlenko, O. V. (2021). Overview of antidepressants on the pharmaceutical market of Ukraine and dynamics of their consumption during 2015-2019. Farmatsevtychnyi Zhurnal, 3, 3–13. doi: https://doi.org/10.32352/0367-3057.3.21.01
  13. Tkachova, O., Kovalenko, L. (2021). Porivnialnyi analiz spozhyvannia antydepresantiv v Ukraini ta Estonii. Molodyi vchenyi, 12 (100), 6–10. doi: https://doi.org/10.32839/2304-5809/2021-12-100-2
  14. Morozov, A. M., Yakovlieva, L. V., Stepanenko, A. V. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy. Kharkiv: Styl-Izdat, 34.
  15. Estonian Statistics on Medicines (2022). Available at: https://www.ravimiamet.ee/en/news/estonian-annual-statistics-medicines-2022
  16. Drug Consumption in Norway 2017–2021 (2022) Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database.
  17. Mishchenko, O. Ya., Bezditko, N. V. (2023). Estsytalopram – antydepresant novoi heneratsii: vid naukovykh danykh do praktychnoho vykorystannia. Zdorovia Ukrainy, 1-2 (537-538), 33–35.
  18. Sanchez, C., Reines, E. H., Montgomery, S. A. (2014). A comparative review of escitalopram, paroxetine, and sertraline. International Clinical Psychopharmacology, 2 (4), 185–196. doi: https://doi.org/10.1097/yic.0000000000000023
  19. Guo, H.-R., Huang, B.-L., Wang, Y.-L., Zhang, Y.-Y., Ma, Q.-G., Lv, P.-P., Ren, Y.-M. (2020). Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive–Compulsive Disorder Rats. Cellular and Molecular Neurobiology, 40 (6), 991–997. doi: https://doi.org/10.1007/s10571-020-00788-4
  20. Dionisie, V., Ciobanu, A. M., Toma, V. A., Manea, M. C., Baldea, I. Et al. (2021). Escitalopram Targets Oxidative Stress, Caspase-3, BDNF and MeCP2 in the Hippocampus and Frontal Cortex of a Rat Model of Depression Induced by Chronic Unpredictable Mild Stress. International Journal of Molecular Sciences, 22 (14), 7483. doi: https://doi.org/10.3390/ijms22147483
  21. Martocchia, A., Curto, M., Scaccianoce, S., Comite, F., Xenos, D., Nasca, C., Falaschi, G. M., Ferracuti, S., Girardi, P., Nicoletti, F., Falaschi, P. (2014). Effects of escitalopram on serum BDNF levels in elderly patients with depression: a preliminary report. Aging Clinical and Experimental Research, 26 (4), 461–464. doi: https://doi.org/10.1007/s40520-014-0194-2
  22. Berger, W., Mehra, A., Lenoci, M., Metzler, T. J., Otte, C., Tarasovsky, G. et al. (2010). Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34 (7), 1279–1284. doi: https://doi.org/10.1016/j.pnpbp.2010.07.008
  23. Xu, Y., Wei, H., Zhu, Y., Zhu, Y., Zhang, N., Qin, J., Zhu, X., Yu, M., Li, Y. (2019). Potential serum biomarkers for the prediction of the efficacy of escitalopram for treating depression. Journal of Affective Disorders, 250, 307–312. doi: https://doi.org/10.1016/j.jad.2019.03.008
  24. Kopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., de Vries, E. F. (2017). Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. Journal of Psychopharmacology, 31 (9), 1149–1165. doi: https://doi.org/10.1177/0269881117711708
  25. Wei, F., Zhou, L., Wang, Q., Zheng, G., Su, S. (2022). Effect of Compound Lactic Acid Bacteria Capsules on the Small Intestinal Bacterial Overgrowth in Patients with Depression and Diabetes: A Blinded Randomized Controlled Clinical Trial. Disease Markers, 29, 672–695. doi: https://doi.org/10.1155/2022/6721695
Comparative analysis of the consumption of antidepressants in Ukraine, Estonia and Norway

Downloads

Published

2023-06-30

How to Cite

Tkachova, O., Iakovlieva, L., Gerasymova, O., Butko, Y., & Kovalenko, L. (2023). Comparative analysis of the consumption of antidepressants in Ukraine, Estonia and Norway. ScienceRise: Pharmaceutical Science, (3(43), 23–30. https://doi.org/10.15587/2519-4852.2023.281833

Issue

No. 3(43) (2023)

Section

Pharmaceutical Science

License

Copyright (c) 2023 Oksana Tkachova, Larysa Iakovlieva, Olga Gerasymova, Yaroslava Butko, Liliia Kovalenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.